Alpha 2.0
Login Register
» Authors » Amy C Gross

Amy C Gross

Explore the profile of Amy C Gross including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 59
Citations 733
Followers 0
Related Specialties
Endocrinology
Pediatrics
Oncology
Top 10 Co-Authors
Claudia K Fox
Aaron S Kelly
Kyle D Rudser
Justin R Ryder
Ryan D Roberts
Eric M Bomberg
Megan O Bensignor
Maren Cam
Carolyn T Bramante
Matthew V Cannon
Published In
Pediatr Obes
Obesity (Silver Spring)
J Pediatr
Child Obes
Curr Obes Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Parent and Guardian Opinions on Obesity Medications Use in Adolescents with Obesity and Related Comorbidities
Raatz S, Freese R, Jang S, Kunin-Batson A, Gross A, Bensignor M
Child Obes . 2024 Dec; PMID: 39694534
There are now four FDA-approved anti-obesity medications (AOMs) for youth ≥12 years, which can be effective therapies to treat obesity and obesity-related comorbidities. This study describes parent/guardian (caregiver) openness to...
2.
Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells
Reinecke J, Jimenez Garcia L, Gross A, Cam M, Cannon M, Gust M, et al.
Clin Cancer Res . 2024 Nov; 31(2):414-429. PMID: 39540841
Purpose: Lung metastasis is responsible for nearly all deaths caused by osteosarcoma, the most common pediatric bone tumor. How malignant bone cells coerce the lung microenvironment to support metastatic growth...
3.
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma
Ringwalt E, Currier M, Glaspell A, Chen C, Cannon M, Cam M, et al.
Mol Ther Oncol . 2024 Nov; 32(4):200886. PMID: 39492947
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucidated. Here...
4.
Multidisciplinary approach to optimizing long-term outcomes in pediatric kidney transplant recipients: multifaceted needs, risk assessment strategies, and potential interventions
Gu L, Gross A, Kizilbash S
Pediatr Nephrol . 2024 Oct; 40(3):661-673. PMID: 39356298
The post-transplant course of pediatric kidney transplant recipients is marked by a myriad of challenges, encompassing medical complications, recurrent hospitalizations, physical and dietary restrictions, and mental health concerns such as...
5.
Effectiveness and predictors of weight loss response to phentermine plus lifestyle modifications among youth in a paediatric weight management clinical setting
Bomberg E, Clark J, Rudser K, Gross A, Kelly A, Fox C
Pediatr Obes . 2024 Jun; 19(8):e13143. PMID: 38886982
Background: Anti-obesity medications (AOMs) are promising lifestyle modification (LSM) adjuncts for obesity treatment, and phentermine is commonly prescribed in paediatric weight management clinics. Determining 'real-world' AOM effectiveness and characteristics predicting...
6.
Financial Incentives and Treatment Outcomes in Adolescents With Severe Obesity: A Randomized Clinical Trial
Gross A, Freese R, Bensignor M, Bomberg E, Dengel D, Fox C, et al.
JAMA Pediatr . 2024 Jun; 178(8):753-762. PMID: 38884967
Importance: Adolescent severe obesity is usually not effectively treated with traditional lifestyle modification therapy. Meal replacement therapy (MRT) shows short-term efficacy for body mass index (BMI; calculated as weight in...
7.
Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting
Bomberg E, Clark J, Rudser K, Gross A, Kelly A, Fox C
Front Endocrinol (Lausanne) . 2024 May; 15:1369270. PMID: 38800488
Introduction: Obesity affects approximately 20% of U.S. youth. Anti-obesity medications (AOMs) are promising lifestyle modification adjuncts for obesity treatment, and topiramate is commonly prescribed in pediatric weight management clinics. It...
8.
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma
Ringwalt E, Currier M, Glaspell A, Chen C, Cannon M, Cam M, et al.
bioRxiv . 2024 Mar; PMID: 38464161
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucidated. Here...
9.
Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity
Bensignor M, Kelly A, Kunin-Batson A, Fox C, Freese R, Clark J, et al.
Pediatr Obes . 2024 Feb; 19(5):e13105. PMID: 38339799
Introduction: Whilst glucagon-like peptide-1 receptor agonists (GLP1-RAs) are effective for treating adolescent obesity, weight loss maintenance (WLM; preventing weight regain) remains a challenge. Our goal was to investigate appetite/satiety hormones...
10.
Appetitive and psychological phenotypes of pediatric patients with obesity
Fox C, Molitor S, Vock D, Peterson C, Crow S, Gross A
Pediatr Obes . 2024 Jan; 19(4):e13101. PMID: 38290813
Background: Obesity is a heterogeneous disease with variable treatment response. Identification of the unique constellation of contributors to obesity may allow for targeted interventions and improved outcomes. Objective: Identify empirically...